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Myometrial infiltration represents a main clinical determinant of 
endometrial carcinomas (EC) presenting as aggressive high-grade 
deeply invasive neoplasms, substantially associated with risk of 
recurrence and death. The up-regulation of ETV5 transcription 
factor linked to the promotion of epithelial to mesenchymal tran-
sition is considered as a basic mechanism underlying the initial 
steps of EC invasion. In this work, we aimed to investigate the 
transcription program of tumor invasion regulated by ETV5. We 
performed a comparative Chip-on-chip analysis at invasive front 
and superficial area of human EC. ETV5 specific binding to pro-
moter regions of genes related to cellular migration, adhesion and 
invasion at deep invasion tumor areas highlighted the relevance of 
neural networks associated with cellular plasticity. Interestingly, 
brain-derived neurotrophic factor (BDNF) demonstrated a 
principal role orchestrating ETV5-mediated epithelial-to-mes-
enchymal transition in endometrial cancer. Impairment of the 
BDNF/tropomyosin-related kinase B (TrkB)/extracellular signal-
regulated kinase axis in endometrial cancer cell lines reversed the 
aggressive and invasive phenotype promoted by the up-regulation 
of ETV5 at the invasive front of EC. Likewise, BDNF directly 
impacted on the efficiency of ETV5 promoted metastasis in a mice 
model of endometrial distant dissemination. These results trans-
late the recognized role of BDNF/TrkB on neural plasticity into 
a relevant cancer metastasis event; suggest common mechanisms 
shared by neural development and tumor invasion; and offer new 
therapeutic opportunities specifically directed against dissemi-
nated disease in endometrial cancer.
Introduction
Endometrial carcinomas (EC), the most common tumors of the female 
genital tract, are usually diagnosed at an early stage with uterine-con-
fined disease and an overall favorable prognosis. However, up to 20% 
of EC present as aggressive neoplasms such as high-grade or deeply 
invasive lesions, at substantial risk of recurrence and death (1). Tumor 
invasion defines the frontier between tissue-restricted carcinoma and 
disseminated tumor cells, with myometrial infiltration, lymph node 
involvement and lymphovascular space invasion as current clinical 
parameters defining the probability of recurrent disease. Regarding 
therapeutic options, radiotherapy and chemotherapy have shown 
limited efficacy and personalized therapy is still a promise when dis-
semination and metastasis are present. Therefore, understanding the 
molecular events related to myometrial infiltration and distant metas-
tasis represents a decisive requirement for the correct management of 
advanced EC.
A recent example of how comprehensive molecular characterization 
of endometrial tumors might identify principal triggers of key clini-
cal challenges as tumor invasion and relapse, linked alterations in the 
PI3K/PTEN/AKT/mTOR pathway with epithelial–mesenchymal tran-
sition (EMT) and advanced events in EC progression (2,3). Indeed, 
main features of EMT provide clues on myometrial invasion in EC (4). 
Our group has recently described the role of ETV5 transcription factor 
in the promotion of EMT associated with the initial steps of endo-
metrial tumor invasion, in cooperation with lipoma-preferred partner 
protein as sensor of extracellular signals (5). In addition, up-regulation 
of ETV5 in stage IB EC correlated with MMP-2 activity at the invasive 
front (6). In this work, we aimed to analyze the transcriptional program 
coordinated by ETV5 specifically at the invasive front of EC. For this, 
we (i) performed a comparative ChIP-on-chip analysis at paired super-
ficial and deep invasive areas of human EC; (ii) we identified clues on 
regulation of genes related to neural plasticity; and (iii) we functionally 
validated, both in vitro and in vivo, the impact of brain-derived neuro-
trophic factor (BDNF) on the ETV5-dependent promotion of EMT and 
invasive abilities in endometrial cancer.
Materials and methods
Patient samples
Fresh-frozen tissue from endometrioid type EC stage IB according to FIGO was 
obtained from 13 women who underwent surgery at Vall d’Hebron University 
Hospital (Barcelona, Spain). Informed consent approved by the correspondent 
ethical committee was signed by all patients. Each sample was evaluated by a 
pathologist in order to macroscopically dissect the invasive front and the superfi-
cial zone of each tumor immediately after surgery. Frozen sections were stained 
with hematoxylin and eosin (H&E) to evaluate the presence of tumor cells: at the 
surface, tumor cells predominated representing 80–90% of cells (left upper image 
in Figure 1B). At the invasive front, tumor cells were admixed with reactive stroma, 
inflammatory cells and myometrial smooth muscle cells; samples included in the 
study presenting at least 70% of tumor cells (right upper image in Figure 1B).
Cell lines and cell culture
Human EC cell lines Hec1A and Hec1A stably expressing the ETV5 tran-
scription factor (H-ETV5) were maintained as described (6) (authentication 
of Hec1A cells has been confirmed at IdentiCell (Denmark) in October 2013 
by GenePrint® 10 System allowing co-amplification and three-color detec-
tion of nine human loci, including the ASN-0002 loci (TH01, TPOX, vWA, 
Amelogenin, CSF1PO, D16S539, D7S820, D13S317 and D5S818) as well as 
D21S11. These loci collectively provide a genetic profile with a random match 
probability of 1 in 2.92 × 109). To stably silence BDNF expression Hec1A 
and H-ETV5 cells were infected with shRNA non-mammalian target control 
(shCtrl) or BDNF-specific shRNA lentiviral particles (shBDNF; NM_001709; 
shBDNF#2 in Supplementary Table  2, available at Carcinogenesis Online) 
in the presence of polybrene (8 µg/ml; Sigma, St. Louis, MO), and selected 
with puromycin (1  µg/ml). Efficacy of infection was assessed by quantita-
tive real time PCR (RT-q-PCR) and western blotting. Endometrial cell lines 
were infected with lentiviruses bearing pLenti CMV V5-LUC Blast (w567-1) 
(Addgene, Cambridge, MA) to constitutively express the luciferase reporter 
gene for in vivo monitoring of tumor implants, as described previously (7). 
Infected cells stably expressing luciferase were selected with blasticidine S 
HCl (3 µg/ml; Invitrogen, Carlsbad, CA).
Chromatin immunoprecipitation, microarray hybridization (ChIP-on-chip) 
and data analysis
ChIP-on-chip was performed following GeneChip Human Tiling 1.0R Array 
Set manufacturer’s instructions (Affymetrix, Santa Clara, CA). Briefly, 
Abbreviations: BDNF, brain-derived neurotrophic factor; ChIP, chromatin 
immunoprecipitation; EC, endometrial carcinoma; EMT, epithelial-to-mesenchy-
mal transition; IgG, immunoglobulin G; RT-q-PCR, quantitative real-time PCR; 
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upon chromatin cross-linking in 1% formaldehyde, tissue from paired sam-
ples corresponding to the superficial zone and invasive front from six ECs 
(30 mg) was disaggregated in 600 μl of ChIP lysis buffer (protease inhibitor 
cocktail, 50 mM Tris–HCl pH 8.0, 10 mM ethylenediaminetetraacetic acid, 
1% sodium dodecyl sulfate). After sonication (Branson sonifier 150; 
Biogen), chromatin fragments (200–1000 bp) were pre-cleared with 
100  μl of Protein G Agarose/Salmon Sperm DNA beads (Millipore, 
CA). Immunocomplexes of chromatin fragments and ETV5 antibodies 
(10  µg; Santa Cruz Biotechnologies, CA) or irrelevant Immunoglobulin 
G (IgG) as negative control (10  µg; Santa Cruz Biotechnologies), were 
recovered with Protein G beads (60 μl) and de-cross-linked (5M NaCl at 
65°C overnight). Resulting DNA was purified using the QIAquick PCR 
purification kit (Qiagen, Hilden, Germany), labeled with GeneChip WT 
Double-Stranded DNA Terminal Labeling Kit (Affymetrix) and hybridized 
to GeneChip Human Tiling 1.0R Arrays (Affymetrix) for 16 h at 45°C and 
60 r.p.m., according to supplier’s instructions. GeneChips were scanned 
with the Affymetrix GeneChip scanner 3000 TG Plus and data from.
CEL files (Affymetrix GeneChip Operating Software, GCOS, v1.2) were 
imported into the Partek Genomic Suite Software, pre-normalized using 
the Robust Multichip Averaging algorithm (Partek, MO) and converted to 
log2. Mean signal from each probe corresponding to the superficial tumor 
zone was subtracted to that of the corresponding invasive area. Promoter 
regions with positive signals representing preferential ETV5 occupation 
sites at the invasive front were selected. Statistical parameters were set at P 
≤ 0.005 (paired t-test). By using Ingenuity Pathway Analysis 2.0 software 
(Ingenuity Systems), genes related with tumor invasion, cellular migra-
tion and metastasis were selected to identify functional pathways and gene 
interaction networks characterizing those promoter genes significantly 
regulated by ETV5 at the invasive front of EC.
BDNF promoter ChIP
Immunoprecipitated DNA was analyzed by PCR using previously designed prim-
ers for BDNF promoter (Forward: 5′-GTGACCACCCAGGTGTAGAAT-3′; 
Reverse: 5′-GCA GGAATGTGTGACAGGAAC-3′; annealing temperature 
57°C, 40 cycles). Equal volumes of PCR products were separated on 2% 
acrylamide gels. Data were normalized to input by densitometry with Image 
J software.
RNA extraction and quantitative real-time PCR (RT-q-PCR)
Total RNA from the invasive front and superficial area of frozen tumor sam-
ples (n = 13) was extracted using the MasterPure Complete DNA and RNA 
Purification Kit (Epicentre Biotechnologies, Madison, WI), according to 
manufacturer’s protocol. Alternatively, total RNA was isolated from differ-
ent cell lines using High Pure RNA Isolation Kit (Roche, Applied Science, 
Indianapolis, IN) according to the manufacturer. cDNA synthesis was per-
formed with MuLV Reverse Transcriptase kit (Applied Biosystems, Foster 
City, CA) following manufacturer’s protocol, and RT-q-PCR was performed 
using TaqMan assays (Supplementary Table  3, available at Carcinogenesis 
Online; Applied Biosystems) in an ABI 7500 Real-Time PCR System. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an inter-
nal normalization control. The results were represented as the fold change in 
gene expression relative to GAPDH gene expression (2−ΔΔCt).
Western blot and immunofluorescence
Protein levels from invasive and superficial tumor areas and from cell extracts 
were assessed by western blot or immunofluorescence as described (5), with 
primary antibodies at indicated dilutions (Supplementary Table  4, avail-
able at Carcinogenesis Online) and total extracellular signal-regulated kinase 
(ERK), tubulin and actin as internal controls. Protein signal was detected using 
Immobilon Western Blotting Kit (Millipore, Billerica, MA). BDNF stimula-
tion was performed under serum starved conditions for 24 h and further incu-
bation with recombinant human BDNF (250 ng/ml; Peprotech) for indicated 
times. Cells were harvested in the presence of protein phosphatase inhibitors.
Migration and invasion assays
Migration and invasion assays were performed as described previously (5). 
Moreover, cells were treated or not with the ERK inhibitor, PD98059 (10 µM; 
Calbiochem, Darmstadt, Germany), or tropomyosin-related kinase B (TrkB) 
inhibitor, K252a (Calbiochem), with or without 250 ng/ml recombinan human 
BDNF (Peprotech) for 24 h and 5 days, respectively.
In vivo assay and bioluminescent imaging
Five-week-old female athymic Nude-Foxn1nu mice were purchased from Harlan 
Laboratories (Indianapolis, IN), housed and maintained under specific patho-
gen-free conditions and manipulated in accordance with institutional guidelines 
Fig. 1. (A) ETV5 mRNA levels at the superficial zone and invasive front of endometrial carcinomas detected by RT-q-PCR (Wilcoxon test; **P ≤ 0.01). (B) 
Schematic representation of the ChIP-on-chip experimental procedure. (C) Ingenuity pathways analysis network of genes regulated by ETV5 at the invasive front 
and associated with cellular migration, invasion and adhesion highlighted in grey. Magnification shows BDNF located at the core of the network, suggesting a 
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approved by the correspondent committee for animal care. Mice were divided in 
three groups with Hec1A–shCtrl, H-ETV5–shCtrl or H-ETV5–shBDNF stably 
expressing luciferase cells (5 × 105 cells in 100 μl of sterile phosphate-buffered 
saline) being inoculated into animals by intracardiac injection under 2% isoflu-
rane/air anesthesia. A successful intracardiac injection was indicated on day 0 by 
images showing systemic bioluminescence distributed throughout the animal. 
Five animals per group, with evidence of a satisfactory injection, continued in 
the experiment. Three weeks after cells injection and before killing, IVIS sys-
tem (Xenogen, Caliper Life Sciences, PerkinElmer, Waltham, MA) coupled to 
Living Imaging software 4.2 (Xenogen) were used to detect tumor lesions by 
bioluminescent imaging. For non-invasive bioluminescence tumor imaging, 
luciferin (Firefly Luciferin, Caliper Life Science, Hopkinton, MA) was used as 
the substrate for the luciferase expressing tumor cells and injected intraperito-
neally at a concentration of 150 mg/kg in phosphate-buffered saline.
Statistical analysis
Statistical analyses were conducted using SPSS (Chicago, version 15.00 for 
Windows) and GraphPad Prism 4.00 software (GraphPad Softwares, San 
Diego, CA). Wilcoxon signed test was used to determine the differences in 
relative gene expression between paired superficial zone and invasive front of 
EC. For other analysis Mann–Whitney and Kruskal–Wallis (followed Dunn’s 
post-test) non-parametric tests were used to determine the differences between 
conditions. Statistical significance was set at P ≤ 0.05.
Results
ETV5-transcription program at invasion front of EC
Paired samples of deep invasive front and superficial areas from EC 
(n = 13) were macroscopically dissected with a minimal of 70–80% 
tumor epithelial component, respectively (see Materials and meth-
ods). Total RNA was extracted and differential relative expression lev-
els of ETV5 transcription factor at the areas of myometrial infiltration 
were confirmed by RT-q-PCR (n = 13; P = 0.0017; Figure 1A). We 
then explored the differential transcriptional program that the specific 
up-regulation of ETV5 might be triggering at the invasive front of EC. 
For this, we performed an ETV5-driven ChIP-on-chip comparative 
analysis at paired tumor areas (deep invasive versus superficial) of EC 
(n = 6). Briefly, fresh tumor tissue from the invasive front and super-
ficial area of EC was used for ChIP with antibodies directed against 
ETV5 transcription factor. As a control or readout of technical effi-
ciency, differential promoter occupation of ETV5 at the deep invasive 
versus corresponding superficial areas was confirmed by evaluation 
of the known ETV5 target cyclooxygenase-2 (COX2) promoter gene 
(8); ETV5-immunoprecipitated DNA demonstrated an enrichment of 
COX2 promoter region (n = 10; Supplementary Figure 1A, available 
at Carcinogenesis Online). Purified DNA was further processed for 
amplification and fragmentation following manufacturer’s instruc-
tions for hybridization onto Affymetrix promoter arrays (Human 
Tilling Arrays, Affymetrix) (Figure  1B). Data mining with Partek 
analysis software resulted in a list of 1523 differentially occupied 
promoter regions between invasive front and superficial areas of EC 
(P ≤ 0.005; GEO accession no. GSE57870).
Further filtering with Ingenuity Pathway Analysis software to com-
prehensively analyze those gene pathways and networks that might 
be related to myometrial infiltration (cellular migration, adhesion or 
invasion), resulted in a list of 104 ETV5-occupied promoter’s gene 
eventually responsible for ETV5-dependent promotion of tumor 
invasion in EC (Supplementary Table 1, available at Carcinogenesis 
Online). Main biological functions associated with ETV5-occupied 
promoter regions at the invasive front pointed to cell-to-cell signal-
ing interaction, organ development, cellular movement, and connec-
tive tissue disorders. More interestingly, development and function of 
nervous system highlighted as the principal network characterizing 
an ETV5-regulated transcription program of endometrial tumor inva-
sion (Figure 1C). This neural network, orchestrated by Pkc signaling 
pathway in cooperation with Akt and ERK1/2, identified BDNF at the 
core suggesting a principal role in the ETV5-transcription program at 
the invasive front in EC (magnification in Figure 1C). The described 
role of ETV5 and neurotrophic factors mediating some features of 
neuronal plasticity, prompted us to further investigate the implication 
of BDNF in ETV5-dependent endometrial tumor invasion.
ETV5 up-regulates BDNF at the invasive front of EC and triggers 
ERK1/2 signaling pathway
The differential occupation of BDNF promoter region by ETV5 tran-
scription factor at the invasive front of EC was confirmed by ChIP 
in paired human samples (Figure  2A). Specific immunoprecipitation 
of BDNF promoter by ETV5 antibodies compared with non-specific 
IgGs was increased at the deep invasive area of EC compared with 
their corresponding superficial areas (n = 6; histogram in Figure 2A). 
Concordantly, the expression levels of BDNF at the invasive area were 
significantly higher compared with those at superficial areas of EC (n 
= 13; P = 0.0215; Figure 2B). This specific up-regulation was linked 
to an enhanced expression of NTRK2 (TrkB) receptor (Figure 2B) and 
the activation of ERK1/2 signaling pathway (Figure 2C), as TrkB is 
known to be coupled to the activation of the RAS (rat sarcoma viral 
oncogene homolog family)/ERK signaling pathways during synaptic 
plasticity (9). Significant relative expression of FYN and NRCAM genes 
at the invasive front of EC reinforced the neural network characterizing 
ETV5-dependent transcription program during myometrial infiltration 
(Supplementary Figure 1B, available at Carcinogenesis Online).
The specific occupation of the BDNF promoter region by ETV5 
was further confirmed in the endometrial cancer cell line Hec1A and 
its ETV5 over-expressing cell line counterpart H-ETV5 (5). As shown 
in Figure  2D, ETV5 antibodies were able to immunoprecipitate 
higher levels of BDNF promoter region in ETV5-overexpressing cells 
compared with the basal levels found in the parental cell line express-
ing basal levels of ETV5. Similar results were obtained with the 
Ishikawa endometrial cancer cell line and its ETV5-overexpressing 
variant (Supplementary Figure  2A, available at Carcinogenesis 
Online). Also concordantly, increased RNA levels of ETV5 resulted 
in enhanced expression of BDNF in H-ETV5 cell line (Figure 2E). 
At the protein level, up-regulation of ETV5 led to an enhanced cyto-
plasmic BDNF expression as evidenced by fluorescent microscopy 
(Figure 2F), and of both the pro- and the mature protein forms shown 
by western blot (Figure 2G). Finally, increased ETV5 transcription 
factor levels leading to an enhanced BDNF expression resulted in the 
activation of ERK1/2 signaling in the endometrial cancer cell line 
Hec1A (Figure 2G). Likewise, addition of BDNF to Hec1A resulted 
in the activation of ERK pathway (Figure 2H), suggesting a feedback 
mechanism of ETV5-dependent modulation of ERK pathway. Similar 
results were obtained in the Ishikawa cell line with up-regulated 
expression of ETV5 (Supplementary Figure 2B and C, available at 
Carcinogenesis Online). All these data link the up-regulation of ETV5 
at the invasive front of EC during the initial steps of myometrial infil-
tration with the activation of the BDNF–TrkB–ERK1/2 axis, a crucial 
signaling pathway related to axonal guidance and plasticity in neural 
development.
BDNF mediates ETV5-dependent EMT in EC cell lines
As mentioned, ETV5 has a direct role on EMT resulting in the 
acquisition of migratory and invasive capabilities in endometrial 
cell lines (5). We thus investigated whether BDNF was intervening 
in ETV5-mediated plasticity; for this, we evaluated in vitro and in 
vivo the impact of BDNF silencing in ETV5 over-expressing cell lines 
(Supplementary Figure 3A, available at Carcinogenesis Online). We 
first confirmed the reversion of the plasticity phenotype promoted 
by the up-regulation of ETV5 in the Hec1A endometrial cancer cell 
line. The acquisition of morphological and mesenchymal biomark-
ers like increased Vimentin or diminished E-cadherin concomitant to 
the up-regulation of ETV5 and BDNF in H-ETV5 cells, was partially 
restored both at the RNA and protein levels by silencing of BDNF 
(Figure 3A). The reversion from a mesenchymal to an epithelial phe-
notype was also evidenced by restoration of EMT-related transcrip-
tions factors upon silencing of BDNF in the ETV5-overexpressing 
Hec1A cells (Supplementary Figure 3B, available at Carcinogenesis 
Online). No impact of BDNF silencing could be observed in the 
parental Hec1A cells with basal levels of ETV5 (data not shown). 
Similar results were obtained in the Ishikawa endometrial cancer cell 
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Interestingly, silencing of BDNF also reversed the activation of ERK 
signaling pathway resulting from the ETV5/BDNF axis in the endo-
metrial cancer cell lines (Figure 3A).
Consistently, the migratory abilities promoted by the up-regulation 
of ETV5 were reversed by silencing of BDNF in H-ETV5 endome-
trial cell line (Figure  4A). Moreover, inhibition of ERK1/2 signal-
ing by specific inhibitor (10 μM PD98059) significantly reduced the 
ETV5–BDNF-mediated Hec1A migration even in the presence of 
human recombinant BDNF (Figure 4A), further supporting the impact 
of BDNF–ERK1/2 axis in ETV5 mediated myometrial infiltration. 
Regarding tumor invasion, in vitro inverted invasion assay also evi-
denced that BDNF silencing reverted the invasive properties devel-
oped by the up-regulation of ETV5 in the Hec1A cells (Figure 4B). 
Consistently, specific inhibition of TrkB (100 nM K252a) resulted in a 
complete abrogation of the migratory properties exhibited by Hec1A 
cells upon activation of the ETV5–BDNF axis (Figure 4A). All these 
results reinforced the mediation of BDNF neurotrophic factor in the 
ETV5-dependent acquisition of a plasticity phenotype in EC lead-
ing to the promotion of migration and invasion during myometrial 
infiltration.
BDNF influences the metastatic efficiency of ETV5-overexpressing 
cells in vivo
We finally evaluated the impact of the reversion of the aggressive plas-
ticity phenotype resulting from the over-expression of the transcrip-
tion factor ETV5, in an in vivo mice model of tumor dissemination. 
For this, we compared the pattern of metastasis upon intra-cardiac 
injection of stably transfected luciferase reporter gene Hec1A cells, 
Fig. 2. (A) Representative PCR analysis of the BDNF promoter region in chromatin immunoprecipitated with anti-ETV5 antibody (ETV5) at the superficial zone 
and invasive front. Irrelevant IgG are shown as negative control (IgG) (left panel). Optical densities of BDNF promoter-enriched chromatin immunoprecipitated 
with anti-ETV5 antibody in the superficial zone and invasive front (Wilcoxon test; *P ≤ 0.05) (histogram in right panel). (B) BDNF and NTRK2 mRNA 
expression levels analyzed by RT-q-PCR in the superficial zone and invasive front (Wilcoxon test; *P ≤ 0.05). (C) Representative western blot images of p-ERK 
in paired samples including superficial zone and invasive front. Total ERK was used as loading control. (D) Validation of ETV5 binding to BDNF promoter 
region in chromatin immunoprecipitated with ETV5 antibody (ETV5) in Hec1A and H-ETV5 cells. Irrelevant IgG are shown as negative control (IgG). (E) 
Analysis of ETV5 and BDNF mRNA levels by RT-q-PCR in Hec1A and H-ETV5 cells (Mann–Whitney test; *P ≤ 0.05, **P ≤ 0.01). (F) Immunofluorescence 
staining for BDNF in Hec1A and H-ETV5 cell lines. DAPI staining was used to detect nuclei. (G) Western blot analysis with antibodies against ETV5, BDNF 
and p-ERK in Hec1A and H-ETV5 cell lines. Total ERK and β-actin were used as a loading control (mBDNF, mature BDNF). (H) Western blot analysis showing 
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Fig. 3. (A) E-cadherin and Vimentin levels in Hec1A–shCtrl, H-ETV5–shCtrl and H-ETV5–shBDNF cells analyzed by RT-q-PCR (histogram in left panel) 
(Kruskal–Wallis test; *P ≤ 0.05, **P ≤ 0.01) and western blot (right panel). Total ERK and β-actin were used as a loading control (right panel). (B) Phase contrast 
microscopy images (upper panels) and immunofluorescence staining for BDNF, E-cadherin and Vimentin (lower panels) in Hec1A–shCtrl, H-ETV5–shCtrl and 
H-ETV5–shBDNF cells. DAPI staining was used to detect the nuclei.
over-expressing or not ETV5 and in the presence or not of BDNF. 
Two representative animals per group are shown in Figure  5, with 
parental Hec1A–shCtrl cells-injected mice presenting metastasis 
implants mainly at bones, ovaries and adrenal glands 3 weeks after 
intra-cardiac injection (n = 5; Figure  5A and B). Up-regulation of 
ETV5 resulted in massive systemic dissemination with implants at 
pancreas, gonadal fat pad and intestine in addition to bones, ovaries 
and adrenal glands (n = 5; Figure  5A and B). Remarkably, silenc-
ing of neurotrophic factor BDNF in ETV5 over-expressing Hec1A 
cells resulted in a reversion of the metastatic pattern (n = 5; Figure 5A 
and B). Quantification of organ-related bioluminescence signal dem-
onstrated the restoration to the less dramatic pattern of metastasis 
dissemination generated by Hec1A endometrial cancer cells upon 
reversion of the ETV5-promoted plasticity phenotype through BDNF 
silencing (Figure 5B). These results further translated into a clinically 
relevant in vivo model the impact of the plasticity phenotype asso-
ciated with the up-regulation of ETV5 during myometrial invasion, 
systemic dissemination and homing at sites of metastasis. In addi-
tion, these in vivo data also reinforced the interplay of BDNF in the 
promotion and modulation of this aggressive phenotype, providing 
with evidences that the known role of the BDNF–TrkB–ERK1/2 axis 
on neuronal plasticity and organogenesis might be mediating pro-
metastatic events triggered by the up-regulation of ETV5 at least in 
endometrial cancer.
Discussion
In this work we have addressed the transcription program underly-
ing ETV5-promotion of myometrial infiltration specifically at the 
invasive front of EC. Notably, we have identified a principal role 
for the ETV5-dependent activation of the BDNF–TrkB–ERK1/2 
axis, relevant in neuronal plasticity. To this regard, PEA3 tran-
scription factor family members ETV4 and ETV5 have been found 
mediating retrograde signaling and axonal growth in response to 
nerve growth factor (10). Likewise, ETV5 has been described as a 
critical mediator of the glial cell line-derived neurotrophic factor 
signaling, acting as an upstream inducer of several genes essen-
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Fig. 4. (A) Transwell migration assay with Hec1A–shCtrl, H-ETV5–shCtrl and H-ETV5–shBDNF cells quantified as relative fluorescence compared with 
Hec1A–shCtrl cells (histogram in left panel) (Kruskal–Wallis test; **P ≤ 0.01). H-ETV5–shCtrl cell migration assays in the presence or absence of BDNF 
with or without PD98059 and K252a treatment (histogram in right panel) (Kruskal–Wallis test; *P ≤ 0.05). (B) GAPDH mRNA levels of cells invaded into 
Matrigel were employed to quantify the relative invasion rate compared with Hec1A–shCtrl cells (histogram in left panel) (Kruskal–Wallis test; **P ≤ 0.01). 
Representative images of confocal microscopy sections with invasive cells stained with calcein acetoxymethyl ester (right panels).
highly conserved neurotrophin in gene structure and function dur-
ing vertebrate evolution, serving an important role during brain 
development and in synaptic plasticity. It participates in the for-
mation of appropriate synaptic connections in the brain, particu-
larly on axon guidance (12). Of note, polymorphisms in ETV5 and 
BDNF have been associated with obesity, maybe through a role in 
neurite outgrowth affecting the development of the energy balance 
circuitry (13,14). Trk receptors are single transmembrane catalytic 
receptors with intracellular tyrosine kinase activity, coupled to the 
Ras/ERK, Cdc42/Rac/RhoG, MAPK, PI3-K and phosphoinositide-
specific phospholipase C (PLC) gamma signaling pathways (15). 
TrkB has highest affinity for BDNF and is involved in neuronal 
plasticity, long-term potentiation and apoptosis of central nervous 
system neurons. BDNF/TrkB axis has in fact been related with 
invasion and metastasis in several types of cancer (16–19).
We previously demonstrated that ETV5 cooperates with lipoma-
preferred partner protein as a sensor of extracellular signals and pro-
motes EMT in EC. ETV5 modulates Zeb1 expression and E-cadherin 
repression leading to a complete reorganization of cell–cell and 
cell–substrate contacts in endometrial cancer (5). Here, we intro-
duced a level of ETV5-dependent EMT modulation through BDNF 
and its known role on plasticity. In line with our results, studies 
with HNSCC (head and neck squamous cell carcinoma) cell lines 
revealed that stimulation with BDNF promoted the migration and 
invasion of HNSCC cells, and both transient and stable suppression 
of TrkB resulted in significant abrogation of constitutive and ligand-
mediated migration and invasion. Furthermore, enforced overexpres-
sion of TrkB results in altered expression of molecular mediators of 
EMT, including down-regulation of E-cadherin and up-regulation of 
Twist (20). TrkB-induced EMT is also related to anoikis resistance 
and metastasis (21). More interestingly, recent evidences suggested a 
direct role of TrkB in endometrial cancer, with increased levels corre-
lated with lymph node metastasis and lymphovascular space involve-
ment (22). TrkB-mediated EMT and promotion of the migratory and 
invasive capacity of endometrial tumor cells reinforced our results 
linking ETV5 and BDNF during the initial events of EC invasion. 
Likewise, TrkB has been involved in a regulatory loop with miR-
204-5p during endometrial tumorigenesis, suggesting restoration of 
miR-204-5p expression as a potential new therapeutic target in EC 
(23). Also in line with recent evidences in EC invasion, expression 
of ERK1/2 has been described to be heterogeneous and, noteworthy, 
p-ERK1/2 expression increased at the myoinvasive front compared 
with the corresponding superficial tumor area of EC (24). The in vivo 
data further reinforced the interplay of BDNF in the promotion and 
modulation of an invasive tumor cell phenotype, and the impact that 
these aggressive cells might ensure in metastasis efficiency.
In summary, we have performed a comparative ChIP-on-chip anal-
ysis at the invasive front of human EC, to identify candidate genes 
involved in ETV5-dependent promotion of myometrial infiltration. 
Bioinformatics highlighted BDNF neurotrophic factor as a main com-
ponent of the gene network that characterized ETV5 transcription at 
the invasive front in EC. In vitro and in vivo studies demonstrated 
the role of BDNF in the modulation of EMT induced by ETV5 and 
the acquisition of cell migratory/invasive capabilities, and the con-
sequent impact on the efficiency of metastasis. To our knowledge, 
this is the first time that ETV5-dependent transcription program of 
invasion provided with new evidences that the known role of the 
BDNF–TrkB–ERK1/2 axis on neuronal plasticity and organogenesis 
might be mediating pro-metastatic events at least in endometrial can-
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like lestaurtinib in early phase clinical trials (25,26), represents a new 
therapeutic expectative for the treatment of high-grade EC.
Supplementary material
Supplementary Table S1–S4 and Figures S1–S4 can be found at http://
carcin.oxfordjournals.org/
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